Compare Lufax Holding Ltd (LU) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs Natera Inc. Common Stock — how do they compare? Lufax Holding Ltd trades at $0.85 (market cap $894.58M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 63.8× Lufax Holding Ltd's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 14 Days and Natera Inc. Common Stock for 0 Days on average.
| LU | NTRA | |
|---|---|---|
Market Cap | $894.58M | $57.03B |
Volume | 1,044,976 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $3.64 | $425.64 |
52-Week Low | $0.86 | $179.42 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $58.66B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lufax Holding Ltd (LU) trades at $0.9201, down 0.47% on the day, reflecting ongoing challenges in China's consumer lending market. The stock shows a bearish technical signal with negative earnings trends, having missed EPS estimates for three consecutive quarters. Recent corporate actions include a 10:1 reverse stock split effective October 2026. Despite deep value metrics (P/S 0.24, P/B 0.07), the company reports negative net income margins and declining revenue, with 2025 showing a $2.10B loss on $23.11B revenue.
LU presents a high-risk opportunity with significant analyst divergence. While 69% of analysts rate it Buy citing deep valuation and Ping An backing, fundamental deterioration and regulatory headwinds create substantial downside risk. The stock's appeal rests on potential capital return catalysts rather than business turnaround, requiring careful risk assessment given China's tightening financial regulations and persistent operational losses.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
